Alnylam Pharmaceuticals (ALNY) Gross Margin (2018 - 2026)
Alnylam Pharmaceuticals posted quarterly Gross Margin of 82.22% for Q1 2026, up 21616.0% year-on-year from N/an in Q1 2025, and up 8.76% on a QoQ basis from 75.6% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 9 years of Gross Margin data on file, last reported at 82.22% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 21616.0% year-over-year to 82.22%; the trailing twelve-month figure through Mar 2026 stood at 81.0% (down 94.0% YoY), and the FY2025 full-year result was 81.77%, down 460.0% from the prior year.
- Gross Margin for Q1 2026 stood at 82.22%, up from 75.6% in the prior quarter.
- Across five years, Gross Margin topped out at 89.8% in Q2 2024 and bottomed at 133.94% in Q1 2025.
- The 5-year median for Gross Margin is 84.21% (2025), against an average of 71.62%.
- The widest annual swing landed in 2025, when Gross Margin slumped 22290 bps; it then jumped 21616 bps in 2026.
- A 5-year view of Gross Margin shows it stood at 86.22% in 2022, then fell by 3 bps to 83.63% in 2023, then slipped by 1 bps to 82.69% in 2024, then fell by 9 bps to 75.6% in 2025, then grew by 9 bps to 82.22% in 2026.
- The last three Gross Margin figures came in at 82.22% (Q1 2026), 75.6% (Q4 2025), and 84.21% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.22% |
| Dec 31, 2025 | 75.60% |
| Sep 30, 2025 | 84.21% |
| Jun 30, 2025 | 81.64% |
| Mar 31, 2025 | -133.94% |
| Dec 31, 2024 | 82.69% |
| Sep 30, 2024 | 83.63% |
| Jun 30, 2024 | 89.80% |
| Mar 31, 2024 | 88.95% |
| Dec 31, 2023 | 83.63% |
| Sep 30, 2023 | 89.41% |
| Jun 30, 2023 | 76.37% |
| Mar 31, 2023 | 87.02% |
| Dec 31, 2022 | 86.22% |
| Sep 30, 2022 | 86.19% |
| Jun 30, 2022 | 84.86% |
| Mar 31, 2022 | 89.00% |
| Dec 31, 2021 | 86.99% |
| Sep 30, 2021 | 85.03% |
| Jun 30, 2021 | 86.28% |
| Mar 31, 2021 | 87.03% |
| Dec 31, 2020 | 86.68% |
| Sep 30, 2020 | 83.45% |
| Jun 30, 2020 | 82.43% |
| Mar 31, 2020 | 86.63% |
| Dec 31, 2019 | 83.01% |
| Sep 30, 2019 | 92.56% |
| Jun 30, 2019 | 90.33% |
| Mar 31, 2019 | 89.95% |
| Dec 31, 2018 | 92.08% |
| Sep 30, 2018 | 93.38% |